Pitcairn Co. Has $262,000 Holdings in Humana Inc. (NYSE:HUM)

Pitcairn Co. decreased its position in shares of Humana Inc. (NYSE:HUM) by 16.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,033 shares of the insurance provider’s stock after selling 203 shares during the period. Pitcairn Co.’s holdings in Humana were worth $262,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. FPC Investment Advisory Inc. acquired a new stake in shares of Humana in the fourth quarter worth $27,000. Centricity Wealth Management LLC acquired a new stake in Humana in the 4th quarter worth $30,000. LFA Lugano Financial Advisors SA increased its holdings in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management acquired a new position in shares of Humana during the fourth quarter valued at about $33,000. Finally, Atwood & Palmer Inc. lifted its stake in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana Price Performance

Shares of HUM stock opened at $253.37 on Monday. The firm has a market cap of $30.58 billion, a price-to-earnings ratio of 25.46, a PEG ratio of 2.05 and a beta of 0.62. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a 50-day moving average price of $267.58 and a 200 day moving average price of $271.55.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Research analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.40%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio (DPR) is currently 35.58%.

Analysts Set New Price Targets

Several brokerages recently issued reports on HUM. Piper Sandler boosted their price target on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Cantor Fitzgerald restated a “neutral” rating and set a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Truist Financial lifted their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Morgan Stanley dropped their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Finally, Barclays lifted their target price on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Eighteen analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $280.17.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.